#CRCTrialsChat

Everyone with #EarlyOnsetCRC wants to know why they were diagnosed with #colorectalcancer.. This month's #CRCTrialsChat #VideoShorts on the @CancerGrand #PROSPECT project explores this question Let's hear from the PIs, Dr. @AndyChanMD & Dr. @yincaoScD! See you tomorrow! #CRCSM

Mississippi has one of the highest colorectal cancer rates in the U.S. Screening saves lives. #ScreenAt45 #TowardsAHealthierMississippi #CRCSM #GetScreened!

March is #ColorectalCancerAwareness Month 💙 When I was diagnosed with rectal cancer, everything changed overnight Even with a science background, nothing prepares you emotionally for hearing the word “cancer.” If you’re going through this, you are not alone #CRCSM @colontown

Fresh off an incredible #GI26. 💙 The COLONTOWN team was proud to present a poster on 5-FU Freedom (via pump self-disconnect), work that grew directly from patient-to-patient convos in our Community! 👉 If you self-disconnect your 5-FU pump, comment with your cancer center.

Congratulations @VanitaNoronha and @TataMemorial team for asking really important questions about the right dose and duration of immunotherapy! We need to address over treatment !! @OncoAlert !

What if we’ve been overdosing immunotherapy all along? In our Ph III DELII study, 20 mg nivolumab q2w beat chemo in OS, with less toxicity, better QoL. It's time to rethink ICI dosing-for science and equity! ascopubs.org/doi/10.1200/JC… @JCO_ASCO @OncoAlert @TataMemorial @SuyogCancer

Incredibly grateful to Andy Chan for presenting our global #EOCRC Think Tank efforts at the #SU2CInnovationSummit. Grateful for the opportunity to highlight this collaborative, international work advancing #colorectalcancerresearch. #cancerresearch @SU2C Learn more about our #GEOCRCTT: fightcolorectalcancer.org/wp-content/upl…

I’ve seen alot of posts recently about pancreatic cancer being “cured” in mice. Just a general reminder of something that is currently hung in my office:

TODAY February 4, 2026: The 6th Annual OncoAlert Colloquium 🚨GI Malignancies REGISTER👉 buff.ly/MjxFItr GI Day 3 Feb 4, 2026 As ALWAYS ✅Patients Included @BenWestphalen 🇩🇪 @GIMedOnc 🇺🇸 @Graokane 🇮🇪 @NiuSanford 🇺🇸 @realbowtiedoc 🇺🇸 @ARosen380 🇺🇸 @Erman_Akkus 🇹🇷 John Herrera Kok🇪🇸 Marco Inama 🇮🇹 @pashtoonkasi @marklewismd @AndresC27622123 @manjuggm @stacy_hurt @KoheiShitara @GillSharlene @FLordick28391 #OncoAlertAF @nataliagandur @acampsmalea @BRicciutiMD @HHorinouchi @FadiHaddad_MD @Abdallah81MD @FernandoOnco @ElisaAgostinett @to_be_elizabeth @bavilima @realbowtiedoc @Erman_Akkus @Lucarecco @GaiaGriguolo @JankovicK @MarioBalsaMD @DrMirallas @OscarTahuahua @UOzkerim @DrRishabhOnco @Onco_Cifu88 @PaulJiL @DaisukeKotani @DraMartinezLago Our Partners @ESGO_society @ESSOnews @CancerCareMASCC @SIOGorg

The #OncoAlertColloquium 2026 GI Malignancies🚨 DAY THREE Presentation by Dr. Nicholas Hornstein🇺🇸 of Northwest Health: Year in Review Upper GI REGISTER HERE TO WATCH: buff.ly/FaS5Cb6 🚨 Practice-changing science in 2025: Upper GI Oncology 🚨 🔹 MATTERHORN🏔️ : Adding perioperative durvalumab to FLOT significantly improves outcomes in resectable gastric/GEJ cancer — marking immunotherapy’s entry into the curative-intent setting for fit, resectable disease. 🔹 DESTINY-Gastric04: Trastuzumab deruxtecan (T-DXd) clearly outperforms ramucirumab-based therapy in 2L HER2+ GEJ, confirming T-DXd as the preferred second-line standard after trastuzumab exposure. 🎯 🔹 HORIZON-GEA-01: Zanidatamab + chemo outperforms trastuzumab-based regimens in 1L HER2+ metastatic GEJ, establishing dual-HER2 blockade as the new frontline backbone. 2025 is reshaping the treatment paradigm in upper GI cancer — more targeted, more effective, and more personalized than ever. #UpperGI #Oncology #GastricCancer #HER2 @BenWestphalen 🇩🇪 @GIMedOnc 🇺🇸 @Graokane 🇮🇪 @NiuSanford 🇺🇸 @realbowtiedoc 🇺🇸 @ARosen380 🇺🇸 @Erman_Akkus 🇹🇷 John Herrera Kok🇳🇱 Marco Inama 🇮🇹 @pashtoonkasi @marklewismd @AndresC27622123 @manjuggm @stacy_hurt @KoheiShitara @GillSharlene @FLordick28391 #OncoAlertAF @nataliagandur @acampsmalea @BRicciutiMD @HHorinouchi @FadiHaddad_MD @Abdallah81MD @FernandoOnco @ElisaAgostinett @to_be_elizabeth @bavilima @realbowtiedoc @Erman_Akkus @Lucarecco @GaiaGriguolo @JankovicK @MarioBalsaMD @DrMirallas @OscarTahuahua @UOzkerim @DrRishabhOnco @Onco_Cifu88 @PaulJiL @DaisukeKotani @DraMartinezLago

The #OncoAlertColloquium 2026 GI Malignancies🚨 DAY THREE Presentation by Dr. Grainne O'Kane🇮🇪 of St Vincent's University Hospital: Year in #PancreaticCancer REGISTER HERE TO WATCH: buff.ly/xwD5G2D The management of pancreatic cancer is likely to change dramatically in the coming years. 🔄🧬 In 2025, a number of key publications evaluated different therapeutic regimens for resectable and borderline resectable disease, with CASSANDRA meeting its primary endpoint of EFS, favouring the PAXG regimen. 📊 Our understanding of PDAC biology continues to expand, and in 2026 all patients with advanced PDAC (and ideally early-stage disease) should undergo molecular profiling to determine KRAS status (KRASm vs WT), HRD, and MMRd. Additional biomarkers are emerging, including MTAP loss. 🧪 An appreciation of RAS dosage and cell states—including basal-like and classical—is likely to be critical for rational combination strategies. The most pivotal change in 2025 has been the advent of RAS inhibitors beyond G12C. 🎯 Targeting KRAS may be allele-specific, while more advanced approaches now include pan-RAS inhibitors. Small molecules, protein degraders, and vaccines are all in clinical trials, with highly anticipated phase 3 results pending. These agents are likely to move rapidly into early-stage disease, underscoring an impending revolution in the management of PDAC. 🔥 GI Oncology @BenWestphalen 🇩🇪 @GIMedOnc 🇺🇸 @Graokane 🇮🇪 @NiuSanford 🇺🇸 @realbowtiedoc 🇺🇸 @ARosen380 🇺🇸 @Erman_Akkus 🇹🇷 John Herrera Kok🇳🇱 Marco Inama 🇮🇹 @pashtoonkasi @marklewismd @AndresC27622123 @manjuggm @stacy_hurt @KoheiShitara @GillSharlene @FLordick28391 #OncoAlertAF @nataliagandur @acampsmalea @BRicciutiMD @HHorinouchi @FadiHaddad_MD @Abdallah81MD @FernandoOnco @ElisaAgostinett @to_be_elizabeth @bavilima @realbowtiedoc @Erman_Akkus @Lucarecco @GaiaGriguolo @JankovicK @MarioBalsaMD @DrMirallas @OscarTahuahua @UOzkerim @DrRishabhOnco @Onco_Cifu88 @PaulJiL @DaisukeKotani @DraMartinezLago Our Partners @ESGO_society @ESSOnews @CancerCareMASCC @SIOGorg

The #OncoAlertColloquium 2026 GI Malignancies🚨 DAY THREE Presentation by Dr. Benedikt Westphalen🇩🇪 of University of Munich: Tumor Agnostic Therapeutics REGISTER HERE TO WATCH: buff.ly/xwD5G2D 🚀 Practice-changing science in 2025: Tumor-agnostic therapeutics 🧬 Comprehensive molecular tumor profiling continues to expand as the number of molecularly guided treatment options rapidly grows across cancer types. Precision oncology is no longer niche—it’s becoming standard. 🔍 HER2 targeting is now broadly established beyond traditional indications, with new therapeutic options actively entering the clinic. 🎯 At the same time, several emerging tumor-agnostic targets are reshaping treatment paradigms, including (K)RAS, MET, MTAP, and NRG1—opening new avenues for biomarker-driven care across histologies. 2025 marks a pivotal year where biology, not tumor origin, increasingly guides therapy. #PrecisionOncology #TumorAgnostic #MolecularProfiling #Oncology GI Oncology @BenWestphalen 🇩🇪 @GIMedOnc 🇺🇸 @Graokane 🇮🇪 @NiuSanford 🇺🇸 @realbowtiedoc 🇺🇸 @ARosen380 🇺🇸 @Erman_Akkus 🇹🇷 John Herrera Kok🇳🇱 Marco Inama 🇮🇹 @pashtoonkasi @marklewismd @AndresC27622123 @manjuggm @stacy_hurt @KoheiShitara @GillSharlene @FLordick28391 #OncoAlertAF @nataliagandur @acampsmalea @BRicciutiMD @HHorinouchi @FadiHaddad_MD @Abdallah81MD @FernandoOnco @ElisaAgostinett @to_be_elizabeth @bavilima @realbowtiedoc @Erman_Akkus @Lucarecco @GaiaGriguolo @JankovicK @MarioBalsaMD @DrMirallas @OscarTahuahua @UOzkerim @DrRishabhOnco @Onco_Cifu88 @PaulJiL @DaisukeKotani @DraMartinezLago Our Partners @ESGO_society @ESSOnews @CancerCareMASCC @SIOGorg

The #OncoAlertColloquium 2026 GI Malignancies🚨 DAY THREE Presentation by Dr. Nina Sanford 🇺🇸 of UT Southwestern: Year in Review GI Radiotherapy REGISTER HERE TO WATCH: buff.ly/xwD5G2D In 2025 ☢️several pivotal trials in gastrointestinal cancers were presented, further positioning radiotherapy as a central component of modern, integrated cancer care. 📊🎯 For HCC, radiotherapy is now included across all major guidelines—including BCLC—as a standard option. 🧠✔️ In pancreatic cancer, PREOPANC2 establishes pre-operative RT as an option for borderline resectable disease, while ongoing trials such as NRG GI011 will hopefully clarify the role of dose-escalated RT in locally advanced tumors. 🔬 In rectal cancer, the JANUS trial has completed accrual and will evaluate whether triplet chemotherapy can improve rates of clinical complete response. 📈 In gastric and GEJ cancers, MATTERHORN established FLOT plus immunotherapy as a new standard of care; however, radiation remains standard for squamous cell cancers and should be considered in patients at risk for a positive surgical margin or those seeking organ preservation. 🧬 Lastly, the PLATO studies in anal cancer support dose de-escalation for early-stage disease and suggest that, in locally advanced disease, uniform dose escalation does not confer benefit. ⚖️ Together, these advances underscore that continued progress in GI cancer radiotherapy depends on clinical trial participation and multidisciplinary collaboration, ensuring evidence-based strategies are delivered safely and effectively to the patients most likely to benefit. 🤝 #RadOnc GI Oncology @BenWestphalen 🇩🇪 @GIMedOnc 🇺🇸 @Graokane 🇮🇪 @NiuSanford 🇺🇸 @realbowtiedoc 🇺🇸 @ARosen380 🇺🇸 @Erman_Akkus 🇹🇷 John Herrera Kok🇳🇱 Marco Inama 🇮🇹 @pashtoonkasi @marklewismd @AndresC27622123 @manjuggm @stacy_hurt @KoheiShitara @GillSharlene @FLordick28391 #OncoAlertAF @nataliagandur @acampsmalea @BRicciutiMD @HHorinouchi @FadiHaddad_MD @Abdallah81MD @FernandoOnco @ElisaAgostinett @to_be_elizabeth @bavilima @realbowtiedoc @Erman_Akkus @Lucarecco @GaiaGriguolo @JankovicK @MarioBalsaMD @DrMirallas @OscarTahuahua @UOzkerim @DrRishabhOnco @Onco_Cifu88 @PaulJiL @DaisukeKotani @DraMartinezLago Our Partners @ESGO_society @ESSOnews @CancerCareMASCC @SIOGorg

The #OncoAlertColloquium 2026 GI Malignancies🚨 DAY THREE Presentation by Dr. John Herrera🇪🇸 of ESSO: Year in Review Upper GI Surgery REGISTER HERE TO WATCH: buff.ly/xwD5G2D “Evolving Surgical Strategies in Esophagogastric Cancers: Evidence Synthesis from 2025 Clinical Trials” 🏥 Recent clinical trials in esophagogastric cancers have driven meaningful shifts in surgical decision-making, perioperative planning, and patient selection. This synthesis of 16 studies highlights key changes in the surgical management of oesophagogastric cancers. Practice-changing evidence includes favoring intrathoracic anastomosis (ICAN), use of immunotherapy in MSI-H tumors, and confirmation of the oncological safety of ICG-guided lymphadenectomy. Function-sparing techniques, such as pylorus-preserving and vagus-sparing surgery, demonstrated benefit in early gastric cancer. At the same time, ADIGE results caution against omitting prophylactic drains. ⚖️ Finally, prehabilitation and quality-of-life trials signal new perioperative priorities, while personalized treatment strategies are emerging that may reshape future guidelines. 🚀 GI Oncology @BenWestphalen 🇩🇪 @GIMedOnc 🇺🇸 @Graokane 🇮🇪 @NiuSanford 🇺🇸 @realbowtiedoc 🇺🇸 @ARosen380 🇺🇸 @Erman_Akkus 🇹🇷 John Herrera Kok🇪🇸 Marco Inama 🇮🇹 @pashtoonkasi @marklewismd @AndresC27622123 @manjuggm @stacy_hurt @KoheiShitara @GillSharlene @FLordick28391 #OncoAlertAF @nataliagandur @acampsmalea @BRicciutiMD @HHorinouchi @FadiHaddad_MD @Abdallah81MD @FernandoOnco @ElisaAgostinett @to_be_elizabeth @bavilima @realbowtiedoc @Erman_Akkus @Lucarecco @GaiaGriguolo @JankovicK @MarioBalsaMD @DrMirallas @OscarTahuahua @UOzkerim @DrRishabhOnco @Onco_Cifu88 @PaulJiL @DaisukeKotani @DraMartinezLago Our Partners @ESGO_society @ESSOnews @CancerCareMASCC @SIOGorg

The #OncoAlertColloquium 2026 GI Malignancies🚨 DAY THREE Presentation by Dr. Marco Inama🇮🇹 of ESSO: Year in Review Lower GI Surgery REGISTER HERE TO WATCH: buff.ly/pKfMiwK Lower GI surgical oncology is evolving towards more integrated, pathway-driven care. 🛤️ Surgical strategies are becoming more selective, with quality increasingly recognised as a measurable oncologic outcome. Looking ahead to 2026, further refinement is expected through personalised decision-making, real-world data, and structured adoption of technology. GI Oncology @BenWestphalen 🇩🇪 @GIMedOnc 🇺🇸 @Graokane 🇮🇪 @NiuSanford 🇺🇸 @realbowtiedoc 🇺🇸 @ARosen380 🇺🇸 @Erman_Akkus 🇹🇷 John Herrera Kok🇳🇱 Marco Inama 🇮🇹 @pashtoonkasi @marklewismd @AndresC27622123 @manjuggm @stacy_hurt @KoheiShitara @GillSharlene @FLordick28391 #OncoAlertAF @nataliagandur @acampsmalea @BRicciutiMD @HHorinouchi @FadiHaddad_MD @Abdallah81MD @FernandoOnco @ElisaAgostinett @to_be_elizabeth @bavilima @realbowtiedoc @Erman_Akkus @Lucarecco @GaiaGriguolo @JankovicK @MarioBalsaMD @DrMirallas @OscarTahuahua @UOzkerim @DrRishabhOnco @Onco_Cifu88 @PaulJiL @DaisukeKotani @DraMartinezLago Our Partners @ESGO_society @ESSOnews @CancerCareMASCC @SIOGorg

The #OncoAlertColloquium 2026 GI Malignancies🚨 DAY THREE Presentation by Dr. Erman Akkus🇹🇷 of Ankara University: How I treat GI Cancers with Limiter Resources REGISTER HERE TO WATCH: buff.ly/xwD5G2D A real-world, practice-focused discussion on delivering high-quality care when access is constrained, covering: 🔹 Colorectal & Anal Cancer 🔹 Esophageal & Gastric Cancer 🔹 Hepatocellular Carcinoma 🔹 Pancreatic & Biliary Cancers An important perspective on prioritization, adaptation, and evidence-based decision-making in resource-limited settings. 💡 GI Oncology @BenWestphalen 🇩🇪 @GIMedOnc 🇺🇸 @Graokane 🇮🇪 @NiuSanford 🇺🇸 @realbowtiedoc 🇺🇸 @ARosen380 🇺🇸 @Erman_Akkus 🇹🇷 John Herrera Kok🇪🇸 Marco Inama 🇮🇹 @pashtoonkasi @marklewismd @AndresC27622123 @manjuggm @stacy_hurt @KoheiShitara @GillSharlene @FLordick28391 #OncoAlertAF @nataliagandur @acampsmalea @BRicciutiMD @HHorinouchi @FadiHaddad_MD @Abdallah81MD @FernandoOnco @ElisaAgostinett @to_be_elizabeth @bavilima @realbowtiedoc @Erman_Akkus @Lucarecco @GaiaGriguolo @JankovicK @MarioBalsaMD @DrMirallas @OscarTahuahua @UOzkerim @DrRishabhOnco @Onco_Cifu88 @PaulJiL @DaisukeKotani @DraMartinezLago Our Partners @ESGO_society @ESSOnews @CancerCareMASCC @SIOGorg

After a colorectal cancer diagnosis, @manjuggm used her knowledge of science and research to help others understand the disease and their treatment options. brnw.ch/21wZD1G @paltown1

Today on @worldcancerday I could not think of a better way to celebrate by showing off the proclamation that I just received in the mail declaring MARCH colorectal cancer awareness month in the state of TEXAS! #worldcancerday #unitedbyunique #crcsm #strongarmselfie

Looking forward to talking about what is 🔥 (changing practice) in GI oncology as 2026 starts! It'll be streamed live so enjoy watching from home/clinic/rounding (please don't stream and drive). Tons of great speakers like @NiuSanford @CathyEngMD @Erman_Akkus and @realbowtiedoc ! REGISTER HERE TO WATCH: buff.ly/FaS5Cb6 @OncoAlert @TheGutOncLab

Thrilled to be part of this invited review on #EO #Colorectalcancer annualreviews.org/content/journa… Must-read for primary care doctors, OB/GYNs & the public. If you are curious about #CRC & want to know about risk factors, read this. @OncoAlert @yincaoScD @CancerGrand #CRCSM @BowerSOPH

5-FU pump disconnect #GI26 abstr102 In Japan, "disconnect at home" is standard; patients rarely return to the clinic. Visiting Nurses are widely available (covered by public insurance) to support disconnects, especially for elderly patients. @manjuggm @ASCO @OncoAlert